Authors
Latest:
Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast CancerGretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.
Latest:
Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor ExposureMatthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
Latest:
Dr. Mercado on Evolution of Biopsy Techniques in Lung CancerJorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.
Latest:
Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 PandemicChris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.
Latest:
Key Unmet Needs in Prostate Cancer ManagementBefore centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.
Latest:
Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer TreatmentsNita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.
Latest:
Dr. Botta on the Diagnosis and Treatment of ESCCGregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.
Latest:
Hackensack Meridian JFK University Medical Center Thoracic Surgeons Perform the First Robotic Resection Surgery for Malignant Thymoma with Intraoperative Installation of Heated ChemotherapySurgeons affiliated with Hackensack Meridian JFK University Medical Center’s Advanced Lung and Airway Center successfully performed the first robotic resection of malignant thymoma, a cancer of the thymus gland, followed by installation of heated chemotherapy into the chest.
Latest:
Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCCFrontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Latest:
Emerging Agents and Future of Small Cell Lung CancerJared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.
Latest:
Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid TumorsBrian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.
Latest:
Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast CancerWilliam Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.
Latest:
Dr. Corr on the Utilization of Molecular Profiling in Endometrial CancerBradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.
Latest:
Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple MyelomaThe treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.
Latest:
Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL TreatmentMichael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.
Latest:
Dr. Shereck Highlights a Day In the Life of an Attending PhysicianEvan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.
Latest:
Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung CancerJohn F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.
Latest:
IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell TechnologyAnalyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.
Latest:
Advice for Community Oncologists Treating Patients With R/R MMDrs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.
Latest:
Dr. Danila on Examining Immunotherapy in Early-Stage Prostate CancerDaniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.
Latest:
From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI CancerDaniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.
Latest:
Dr Cardin on the Influence of Comorbidities on Treatment Selection in Pancreatic CancerDana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.
Latest:
Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast CancerRuchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
Latest:
The Impact of CAR T Cell Therapy on Managing R/R LBCLCAR T cell therapies have shown remarkable clinical success in difficult-to-treat blood cancers. Read one oncologist’s perspective on what current CAR T therapies may offer patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including at earlier points in their disease journey.
Latest:
Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast CancerIsmail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast CancerIrene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.
Latest:
MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALLDoug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).
Latest:
Dr. Vijayvergia on the Efficacy of Pembrolizumab in MSI-H Advanced Gastric CancerNamrata (Neena) Vijayvergia, MD, discusses the efficacy of pembrolizumab with or without chemotherapy in patients with microsatellite instability–high advanced gastric cancer.
Latest:
New Trial Tests Chemotherapy Regimen Following Pancreatic Cancer SurgeryA new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
